About this episode

MedPal AI launches a new GLP-1 sub-brand with significant marketing investment ahead of a key product approval.

MedPal AI (AIM: MPAL) launches New Health, a standalone GLP-1 sub-brand backed by £1.3 million of marketing, ahead of expected UK approval of Novo Nordisk’s oral Wegovy. CEO Jason Drummond on the strategy, the market, and the unit economics behind it.

More episodes of The Vox Markets Podcast

• 2409: Prospex Energy: The Bases Are Loaded as Asset Momentum Builds into 2027 · June 1, 2026 · 10 min
• 2408: MedPal Hits Record Prescription Volumes & £5m Run-Rate · June 1, 2026 · 6 min
• 2407: Blencowe boosts Orom-Cross with updated DFS · May 29, 2026 · 8 min
• 2406: 2 P's on a Pod: What’s Next in UK M&A? · May 28, 2026 · 1h 22m
• 2405: ACG Metals set for US$200m EBITDA next year · May 28, 2026 · 16 min
• 2403: The Exchange with Richard Staveley of Rockwood Strategic & Harwood Capital · May 20, 2026 · 1h 20m

Explore listener stats, chart rankings, contacts and more on the The Vox Markets Podcast podcast page.